1-[3-Hydroxy-4-(hydroxymethyl)cyclopentyl]-5-iodopyrimidine-2,4-dione | 87421-98-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: 1-[3-Hydroxy-4-(hydroxymethyl)cyclopentyl]-5-iodopyrimidine-2,4-dione
• CAS: 87421-98-5
• 化学式: C₁₀H₁₃IN₂O₄
• 分子量: 352.129
• InChiKey: NEWOWXPKUVLDTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  89.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[3-Hydroxy-4-(hydroxymethyl)cyclopentyl]-5-iodopyrimidine-2,4-dione 生成 [4-(5-iodo-2,4-dioxopyrimidin-1-yl)-2-(trityloxymethyl)cyclopentyl] methanesulfonate
  参考文献：
  名称：

  HRONOWSKI, LUCJAN J. J.;SZAREK, WALTER A., J. CHEM. SOC. CHEM. COMMUN.,(1990) N1, C. 2547-2548

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(3-hydroxy-4-hydroxymethyl-cyclopentyl)-1H-pyrimidine-2,4-dione 生成 1-[3-Hydroxy-4-(hydroxymethyl)cyclopentyl]-5-iodopyrimidine-2,4-dione
  参考文献：
  名称：

  HRONOWSKI, LUCJAN J. J.;SZAREK, WALTER A., J. CHEM. SOC. CHEM. COMMUN.,(1990) N1, C. 2547-2548

  摘要：

  DOI：

文献信息

• Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
  申请人：——

  公开号：US20030176392A1

  公开（公告）日：2003-09-18

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  提供了一种用于治疗、预防和/或预防寄主，特别是感染了爱泼斯坦-巴尔病毒（EBV）的人类的方法和组合物，包括向寄主施用有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药，可选地还包括药学上可接受的稀释剂或赋形剂。
• Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation
  申请人：Schinazi Raymond F.

  公开号：US20100168052A1

  公开（公告）日：2010-07-01

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  本发明提供了一种用于治疗、预防和/或预防宿主，特别是人类，感染EB病毒（EBV）的方法和组合物，其中包括在药物接受者中给予有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药，可选地在药学上可接受的稀释剂或赋形剂中。
• TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION
  申请人：GILEAD PHARMASSET LLC

  公开号：US20140336143A1

  公开（公告）日：2014-11-13

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  提供一种用于治疗、预防和/或预防寄主，特别是人类，感染EB病毒（EBV）的方法和组合物，其中包括在药学上可接受的稀释剂或赋形剂中投与有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药。
• Cyclopentane derivatives
  申请人：GLAXO GROUP LIMITED

  公开号：EP0418007A2

  公开（公告）日：1991-03-20

  The present invention provides the compound [1R-(1β,3α,4β)]-5- [(E)-2-­bromovinyl]-1-[3-hydroxy-4-(hydroxymethyl)-1-cyclopentyl- 2,4(1H,3H)-­pyrimidinedione and salts and solvates and pharmaceutically acceptable derivatives thereof, and describes processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of viral diseases, especially those caused by the Herpetoviridae.

  本发明提供了化合物[1R-(1β,3α,4β)]-5-[(E)-2-溴乙烯基]-1-[3-羟基-4-(羟甲基)-1-环戊基-2,4(1H,3H)-嘧啶二酮及其盐类、溶剂和药学上可接受的衍生物，并描述了它们的制备过程、含有它们的药物组合物以及它们在治疗病毒性疾病，特别是由赫氏病毒科引起的疾病中的用途。
• HRONOWSKI, LUCJAN J. J.;SZAREK, WALTER A., J. CHEM. SOC. CHEM. COMMUN.,(1990) N1, C. 2547-2548
  作者：HRONOWSKI, LUCJAN J. J.、SZAREK, WALTER A.

  DOI：——

  日期：——